- The study investigated the mechanisms driving irreversible disability in secondary progressive multiple sclerosis (MS), specifically focusing on demyelinating white matter lesion expansion.
- Researchers performed integrated lipidomic, transcriptomic, proteomic, chemical proteomic, and histological analyses on human postmortem MS lesions, and utilized a mouse model of demyelination.
- Lesions containing foamy GPNMB+ microglia/macrophages exhibited disrupted lipid metabolism, lysosomal stress, heightened phagocytosis, and antigen presentation, without classical pro-inflammatory signatures.
- The authors concluded that disturbed lipid metabolism, particularly involving foamy microglia/macrophages, contributes to chronic MS pathology and progressive disease.
- Inhibition of monoacylglycerol lipase (MAGL) promoted lesion recovery and reduced microgliosis in a mouse model, suggesting MAGL as a potential therapeutic target, and cerebrospinal fluid oxylipins may serve as biomarkers for progression.
Unraveling Lesion Progression in Multiple Sclerosis
Multiple sclerosis (MS) is a chronic neuroinflammatory condition characterized by demyelinating white matter lesions that accumulate and expand, contributing to irreversible disability. While current therapies manage relapsing-remitting forms, effectively addressing progressive MS remains a significant unmet need, with ongoing research exploring various avenues to mitigate neuroinflammation and neurodegeneration [1, 2]. The endocannabinoid system, a complex network of receptors, endogenous lipids, and metabolic enzymes, plays a crucial role in modulating neuroinflammation and maintaining brain homeostasis [3, 4, 5]. Specifically, monoacylglycerol lipase (MAGL) is a key enzyme involved in the degradation of the endocannabinoid 2-arachidonoylglycerol, and its inhibition has shown potential in preclinical models of neurodegenerative diseases by resolving neuroinflammation and mitigating neuropathology [6, 7]. A deeper understanding of the cellular and molecular events driving lesion progression is therefore vital for identifying new therapeutic targets and biomarkers.
Identifying a Distinct Microglial Population in Progressive MS
To illuminate the mechanisms driving chronic lesion expansion in multiple sclerosis, a recent study investigated the cellular landscape of human postmortem tissue. The analysis identified a distinct population of foamy GPNMB+ microglia/macrophages specifically associated with lesion expansion in secondary progressive MS. These cells are termed "foamy" due to their lipid-laden appearance under a microscope, a visual sign of altered lipid processing. To characterize these cells, researchers employed an integrated multi-omics approach, combining lipidomics (the study of the full complement of cellular lipids), transcriptomics (gene expression), proteomics (proteins), and chemical proteomics (protein activity) with traditional histological analysis. This comprehensive strategy provided a detailed molecular portrait of progressive lesions, establishing this specific microglial subtype as a key feature of ongoing pathology and a potential focus for interventions aimed at halting disease progression.
Lipid Dysregulation and Cellular Stress in Lesion Expansion
A detailed examination of lesions containing these foamy microglia/macrophages revealed a unique molecular signature. The findings showed that these expanding lesions consistently exhibited disrupted lipid metabolism and signs of lysosomal stress, indicating that the cells' internal waste-disposal systems were overwhelmed. Concurrently, these cells displayed markers of heightened phagocytosis and antigen presentation, suggesting they are actively engulfing debris and communicating with the adaptive immune system. Critically, this activity occurred without the classical pro-inflammatory signatures typical of acute MS relapses. This distinction suggests a smoldering, non-canonical inflammatory process may be responsible for the chronic, steady tissue damage seen in progressive MS. Further analysis specified the nature of the metabolic disruption, finding these lesions were enriched for oxylipins, bismonoacylglycerolphosphates, and cholesterol esters. This lipid accumulation was accompanied by increased B cell infiltration and local deposits of IgG1, pointing to a complex interplay between innate microglial dysfunction and the adaptive immune response in driving chronic pathology.
Monoacylglycerol Lipase Inhibition as a Therapeutic Strategy
The discovery of profound lipid dysregulation within expanding MS lesions prompted an investigation into the underlying enzymatic pathways. This work revealed that Monoacylglycerol lipase (MAGL), a critical enzyme in lipid metabolism, was enriched in lesions containing foamy microglia/macrophages. MAGL is primarily responsible for breaking down the endocannabinoid 2-arachidonoylglycerol, a key signaling molecule in the brain. Its specific abundance in these pathological sites positioned it as a potential therapeutic target for correcting the observed metabolic disturbances. To test this hypothesis, the researchers used a mouse model of demyelination. The results demonstrated that pharmacological inhibition of MAGL promoted lesion recovery and, importantly, also reduced microgliosis, the accumulation of activated microglia at the site of injury. These preclinical findings suggest that targeting MAGL could represent a specific therapeutic strategy to counteract both the lipid-driven pathology and the detrimental microglial activation that characterize chronic lesion progression in MS.
Cerebrospinal Fluid Oxylipins as Progression Biomarkers
In addition to identifying a therapeutic target, the study explored the potential for new biomarkers to monitor progressive MS. Since oxylipins were found to be highly concentrated in expanding lesions, the researchers measured their levels in cerebrospinal fluid (CSF). They discovered that levels of specific oxylipins in the CSF correlate with the proportion of foamy lesions found in postmortem brain tissue. This strong association suggests that CSF oxylipins could function as a liquid biopsy, providing a window into the specific pathological processes occurring within the central nervous system. For clinicians managing a disease with a subtle and gradual progression, such a biomarker could be invaluable. It holds the potential to more accurately track disease activity, stratify patients based on their underlying lesion biology, and objectively measure the response to therapies targeting lipid metabolism, thereby enabling more personalized treatment strategies for patients with progressive MS.
Implications for Chronic MS Pathology
The integrated findings from this study converge on a central theme: disturbed lipid metabolism is deeply implicated in the pathology of chronic multiple sclerosis. The work provides a mechanistic link between a specific cellular phenotype, the foamy GPNMB+ microglia/macrophage, and the molecular environment of expanding lesions in secondary progressive MS. These cells, operating in a state of lysosomal stress and lipid overload, appear to drive a non-classical inflammatory process that contributes to persistent demyelination. Consequently, the study proposes that these foamy microglia/macrophages are a key cell type to target for progressive disease. The identification of enriched Monoacylglycerol lipase (MAGL) in these cells, coupled with evidence that its inhibition can promote recovery in a preclinical model, offers a concrete therapeutic hypothesis. This shifts the focus from broad immunosuppression toward targeting specific metabolic dysfunctions within a defined cell population, offering a more refined strategy for developing therapies that may slow or halt the accumulation of irreversible disability in progressive MS.
References
1. Mecha M, Carrillo‐Salinas FJ, Feliú A, Mestre L, Guaza C. Perspectives on Cannabis-Based Therapy of Multiple Sclerosis: A Mini-Review. Frontiers in Cellular Neuroscience. 2020. doi:10.3389/fncel.2020.00034
2. Călina D, Bugă AM, Mitroi M, et al. The Treatment of Cognitive, Behavioural and Motor Impairments from Brain Injury and Neurodegenerative Diseases through Cannabinoid System Modulation—Evidence from In Vivo Studies. Journal of Clinical Medicine. 2020. doi:10.3390/jcm9082395
3. Hryhorowicz S, Kaczmarek-Ryś M, Zielińska A, Scott RJ, Słomski R, Pławski A. Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease – A Systematic Review. Frontiers in Immunology. 2021. doi:10.3389/fimmu.2021.790803
4. McPartland JM, Guy GW, Marzo VD. Care and Feeding of the Endocannabinoid System: A Systematic Review of Potential Clinical Interventions that Upregulate the Endocannabinoid System. PLoS ONE. 2014. doi:10.1371/journal.pone.0089566
5. Incontro S, Musella ML, Sammari M, Scala CD, Fantini J, Debanne D. Lipids shape brain function through ion channel and receptor modulations: physiological mechanisms and clinical perspectives. Physiological Reviews. 2024. doi:10.1152/physrev.00004.2024
6. Soliman N, Haroutounian S, Hohmann AG, et al. Systematic review and meta-analysis of cannabinoids, cannabis-based medicines, and endocannabinoid system modulators tested for antinociceptive effects in animal models of injury-related or pathological persistent pain. Pain. 2021. doi:10.1097/j.pain.0000000000002269
7. Chen C. Inhibiting degradation of 2-arachidonoylglycerol as a therapeutic strategy for neurodegenerative diseases. Pharmacology & Therapeutics. 2023. doi:10.1016/j.pharmthera.2023.108394